Clinical Trials Logo

Purpura, Thrombocytopenic clinical trials

View clinical trials related to Purpura, Thrombocytopenic.

Filter by:

NCT ID: NCT01101295 Recruiting - Clinical trials for Purpura, Thrombocytopenic, Idiopathic

The ITP-RITUX Cohort: Rituximab in Immune ThrombocytoPenia.

ITP-RITUX
Start date: April 2010
Phase: N/A
Study type: Observational

The primary purpose of the study is to describe by a prospective observational study the serious adverse events occurring in patients treated off-label by rituximab for Immune Thrombocytopenia.

NCT ID: NCT00531089 Recruiting - Clinical trials for Thrombotic Thrombocytopenic Purpura

Rituximab in Patients With Relapsed or Refractory TTP-HUS

Start date: December 2007
Phase: Phase 2
Study type: Interventional

The general objective of this study is to assess the efficacy and safety of Rituximab in the management of patients with refractory or relapsed thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS). There have been several case reports and case series describing the use of Rituximab in patients with TTP-HUS; however its use has not been studied in a large trial. It is hypothesized that Rituximab may ameliorate the severity of certain cases of TTP-HUS by decreasing the number of activity of B-cells which may result in decreased production of the ADAMTS13 protease inhibitor. Patients with TTP-HUS not responding to standard therapy or patients with relapsed disease may have particular benefit. Treatments that decrease the frequency of relapse or shorten the time to remission of TTP-HUS will be of benefit by decreasing the need for blood product support.

NCT ID: NCT00107913 Recruiting - Clinical trials for Autoimmune Thrombocytopenic Purpura

Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura

Start date: September 2001
Phase: Phase 2
Study type: Interventional

This study is designed to evaluate the efficacy and safety of single agent Doxil in the treatment of patients with refractory ITP (Idiopathic Thrombocytopenic Purpura).